Uridine triacetate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Uridine triacetate (Tri-O-acetyl uridine) 是一种具有口服活性的 Uridine (HY-B1449) 前体。Uridine triacetate 能在肠道内迅速被吸收，在循环中迅速脱乙酰，生成游离尿苷。Uridine triacetate 可用于研究 5-氟尿嘧啶 (5-FU) 和卡培他滨的毒性，或早发性心脏或中枢神经系统 (CNS) 毒性。

Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS).

Uridine triacetate inhibits [3H]uridine uptake in ENT1 and ENT2 overexpressed HeLa cells, with IC50s of 28.4 μM and 228.4 μM respectively.

Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced toxicity in 5-FU overdose mice.Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced 5-FU toxicityin DPD deficiency mice.Animal Model:5-FU overdose (i.p., 300 mg/kg) BALB/c mice model Dosage:2 g/kg Administration:Oral gavage, every 8 h for 15 total doses.Result:Improved the survival rate to 90%, 60%,30%, 20%, 0% and 0% in the groups initiated within 24, 48, 72, 96, 120 and 144 h, respectively.Animal Model:5-ethynyluracil-induced (i.p., 2mg/kg) DPD (dihydropyrimidine dehydrogenase) deficiency mice model Dosage:2 g/kg Administration:Oral gavage, every 8 h for 15 total doses.Result:Improved the survival rate to 100% when initiated 4 h after 5-FU, 80% when initiated within 24 h.Improved the survival rate to 40%, 50%,20%, 30% and 0% in groups initiated within 48, 72, 96, 120 and 144 h, respectively.

——

Others

Other Targets

Others

——

——

4105-38-8

370.31

C15H18N2O9

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : ≥ 100 mg/mL (270.04 mM) H2O 中的溶解度 : 10 mg/mL (27.00 mM; 超声助溶)

CC(=O)OCC1OC(C(OC(C)=O)C1OC(C)=O)N1C=CC(=O)NC1=O

——

(-20℃)

With Ice Pack

≥ 2 years